AllSight
Companies · WM · Refuse Systems · Exec change · Aug 26, 2026

WM names John Morris CEO successor as Jim Fish retires after decade at helm

CEO successionpartly known
Internal successor appointed; transition effective January 4, 2027
WASTE MANAGEMENT INC (WM) — what happened, in plain English, and what it means versus what the market expected.

The direction was already being telegraphed, so this is not a surprise succession. Morris had been elevated to President in May 2025 after serving as COO, and the filing explicitly describes his appointment as a continuation of WM’s succession-planning process. 〔0〕 The market likely expected an internal handoff; the new information is the formal timing and confirmation of Morris as the successor.

The handoff is orderly, reducing execution risk. Morris already runs the company as President, joins the board at the transition date, and will take over on January 4, 2027. 〔1〕 Fish is also expected to remain available in an advisory role through mid-February 2027, providing overlap rather than an abrupt departure. 〔2〕

The offsetting issue is the loss of a long-tenured CEO, not uncertainty over who replaces him. Fish is retiring after more than 25 years with WM and more than a decade in the CEO and board roles. 〔3〕 That makes the event strategically meaningful, but the internal promotion and transition overlap keep it from reading as a leadership shock.

Net read: a partly priced-in leadership change with balanced implications. The filing provides continuity and no disclosed strategic reset, but it also removes a proven incumbent whose tenure spans WM’s current operating model. With no earnings, guidance, or capital-allocation change disclosed, the appropriate scorecard is an orderly CEO succession rather than a financial beat or miss.

Read the original 8-K on SEC EDGAR ↗
All WM filings, decoded →
Related companies in Refuse Systems
Latest across the market
DYDycom’s Q2 beats on EPS, but wireless delays blunt the upgradeCRNCCerence repurchases $10M of convertible notes below par, trims debt opportunisticallyBBWIBath & Body Works beats Q2 estimates, but tariff refund masks weak Q3 setupSMMTSummit Therapeutics’ ivonescimab clears biliary-cancer OS bar, but data stay toplineANFAbercrombie & Fitch beats Q2 targets, raises guide—but tariffs inflate EPSBHVNBiohaven lands $400M Kv7 deal, but RISE3 data still decides opakalim’s valueBrowse all companies, decoded →
Open live on AllSight — the whole market, decoded →
AllSight turns SEC filings into plain-English, neutral reads and objective market context. We explain what happened and how it lands versus expectations — we do not give investment advice or predict prices. Decoded straight from the filing; check it against the source.